Thalia Therapeutics plc (AIM: THAT) is advancing its RNA therapy pipeline following a corporate transformation completed in July 2026, which saw the company rebrand from N4 Pharma plc and acquire Sanmirna Therapeutics Inc.
The company, which raised £2.75 million alongside the transformation, now operates three RNA programs led by CEO David Solomon and CFO Luke Cairns.
THAT-001 (miRisten) is Thalia's lead candidate, designed to inhibit microRNA-126, which plays a role in leukemia stem cell survival. The therapy is undergoing a Phase 1 dose-escalation trial in patients with relapsed or refractory acute myeloid leukaemia (AML) at the City of Hope in the United States. Several patient cohorts have been completed. Acute myeloid leukaemia affects more than 22,000 new patients annually in the U.S. Top-line data from the trial is targeted for the first half of 2027.
A second program, THAT-002, is a bispecific siRNA cardiovascular therapy targeting PCSK9 and lipoprotein(a). It has been developed in partnership with WuXi AppTec (Hong Kong) Limited through preclinical synthesis of siRNAs and in vitro and in vivo studies. Thalia expects to advance THAT-002 into IND-enabling non-human primate studies in early 2027.
A third program, THAT-003 (Nuvec), focuses on targeted RNA delivery to the liver via GalNAc. Ex-vivo work is underway in collaboration with the University of Strathclyde.
Thalia announced that it will report interim results for the six months ended June 30, 2026 on September 30, 2026, accompanied by an analyst briefing and investor presentation.
